Trials / Completed
CompletedNCT00506935
Assessment of GVG for the Treatment of Methamphetamine Dependence
Phase 1 Study of Vigabatrin (GVG) for Methamphetamine Dependence
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Baylor College of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out if GVG can reduce drug use and determine safety and effects of GVG when used together with methamphetamine. This study involves staying in the hospital for 21 days. Participants will receive either placebo or GVG, and a limited amount if methamphetamine will be injected on some study days. This study will enroll people that use methamphetamine. Participants will be compensated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GVG | 5 grams GVG |
| DRUG | placebo | placebo |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2008-04-01
- Completion
- 2008-06-01
- First posted
- 2007-07-25
- Last updated
- 2017-07-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00506935. Inclusion in this directory is not an endorsement.